Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Down 71.4% in January

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) saw a significant decrease in short interest in January. As of January 15th, there was short interest totalling 1,200 shares, a decrease of 71.4% from the December 31st total of 4,200 shares. Based on an average daily volume of 11,400 shares, the days-to-cover ratio is presently 0.1 days.

Scinai Immunotherapeutics Stock Performance

Shares of NASDAQ:SCNI traded up $0.04 on Tuesday, hitting $3.57. The company’s stock had a trading volume of 279 shares, compared to its average volume of 8,434. Scinai Immunotherapeutics has a 12 month low of $2.23 and a 12 month high of $8.92. The company has a market capitalization of $3.03 million, a price-to-earnings ratio of -0.01 and a beta of 2.34. The stock’s 50-day moving average is $3.41 and its two-hundred day moving average is $3.64. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.16 and a current ratio of 1.16.

Scinai Immunotherapeutics (NASDAQ:SCNI) last released its quarterly earnings results on Friday, November 22nd. The company reported $8.40 earnings per share (EPS) for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.